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Background: The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from
malignant melanoma to 1 of 4 prognostic groups. It was largely derived using clinical data from patients treated in the era that
preceded the development of newer therapies such as BRAF, MEK and immune checkpoint inhibitors. Therefore, its current
relevance to patients diagnosed with brain metastases from malignant melanoma is unclear. This study is an external validation of
the msGPA in two temporally distinct British populations.
Methods: Performance of the msGPA was assessed in Cohort I (1997–2008, n¼ 231) and Cohort II (2008–2013, n¼ 162) using
Kaplan–Meier methods and Harrell’s c-index of concordance. Cox regression was used to explore additional factors that may have
prognostic relevance.
Results: The msGPA does not perform well as a prognostic score outside of the derivation cohort, with suboptimal statistical
calibration and discrimination, particularly in those patients with an intermediate prognosis. Extra-cerebral metastases,
leptomeningeal disease, age and potential use of novel targeted agents after brain metastases are diagnosed, should be
incorporated into future prognostic models.
Conclusions: An improved prognostic score is required to underpin high-quality randomised controlled trials in an area with a
wide disparity in clinical care.
Metastatic melanoma causes brain metastases in 30–60% of
patients with stage IV disease (Fisher and Larkin, 2012). Treatment
options include best supportive care (including corticosteroids),
radiotherapy, neurosurgery, drug treatment or any combination of
these. Radiotherapy may be delivered as whole brain radiotherapy
(WBRT), stereotactic radiosurgery (SRS) or a combination of these
treatments. Despite this range of available treatments, optimal
management remains unclear and prognosis can vary considerably
and unpredictably. Selecting patients appropriately for the most
suitable treatment approach is extremely important to optimise
outcomes, reduce toxicities and limit the overall financial impact of
treatment. A number of scoring systems have been used, including
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a melanoma-specific RTOG recursive partitioning analysis (RPA)
score (Morris et al, 2004).
More recently, the graded prognostic assessment (GPA)
(Sperduto et al, 2008) has been used as a prognostic index for
patients with brain metastases across tumour types. Similar to the
RPA, this index is based on age, number of brain metastases,
Karnofsky performance status (KPS) and the presence of
extra-cranial metastases. The melanoma-specific GPA (msGPA)
was derived from multivariate Cox regression assessment of these
4 factors in a North American cohort of 483 patients treated for
brain metastases from melanoma between June 1993 and January
2010 (Sperduto et al, 2012). The msGPA is calculated from the
sum of only two components, the KPS and the number of brain
metastases (see Box 1). It may range from 0 to 4 and is
straightforward to calculate at the time of diagnosis of intra-
cerebral disease.
However, these scoring systems must be considered in the context
of the changing landscape of melanoma treatment, resulting from
the emergence of novel targeted agents. Inhibitors of BRAF kinase
(vemurafenib, dabrafenib), MEK (trametinib, cobemetinib), and
immune checkpoints (CTLA4 (ipilimumab) and PD-1 (pembroli-
zumab, nivolumab) have all emerged as active agents in melanoma
and may have intra-cerebral activity in some patients (Fisher and
Larkin, 2012; Long et al, 2012; Margolin et al, 2012; Dummer et al,
2014). The original derivation data set for the msGPA demonstrated
good discrimination between prognostic groups using Kaplan–Meier
(KM) methods (Sperduto et al, 2012). However, there was a
selection bias towards fitter patients in that 76% of patients received
SRS and no patient received best supportive care alone. Critically,
the impact of predictive and prognostic biomarkers (e.g., BRAF/RAS
mutation) and the use of newer targeted agents on survival were not
explicitly considered in that study. Therefore, the current relevance
of the msGPA to patients with brain metastases from malignant
melanoma is uncertain.
In addition, the msGPA has not yet been validated robustly in
the published literature. The study by Royston and Altman (2013)
highlights the importance of validating prognostic indices with
particular reference to a model’s discrimination and calibration.
Ideally, validation should occur in an external cohort that differs in
time, investigators and location with that of the derivation data set
(Royston and Altman, 2013). Therefore, the aim of this study was
to validate the msGPA in two temporally distinct UK cohorts,
including patients treated before and after the emergence of new,
highly active anti-melanoma therapies.
MATERIALS AND METHODS
Electronic patient records for two separate cohorts of patients with
brain metastases from metastatic melanoma were reviewed. Cohort I
was obtained by searching radiotherapy records from 1 July 1997 to
31 July 2008, including all patients treated with radiotherapy, with or
without surgery and drug treatment. Cohort II was obtained by
screening clinic attendance records from 1 August 2008 until 1
August 2013 to identify patients who had brain metastases
diagnosed after 1 August 2008. Cohort II included patients treated
with novel targeted agents and best supportive care. This study was
approved by our institutional review board (SE224).
Data extracted from electronic patient records included basic
demographics (age and sex), date of diagnosis of brain metastases,
number of brain metastases and KPS at the time of diagnosis of
brain metastases. The presence or absence of leptomeningeal
disease and the number of sites of extra-cerebral metastases were
also recorded. Data on the number and type of treatments received
for brain metastases were collected including neurosurgery,
stereotactic radiotherapy and WBRT. Routine BRAF testing began
at our institution in March 2010. Therefore, where available, BRAF
mutation status was recorded. Details of treatment with novel
targeted agents, started after the diagnosis of brain metastasis, were
collected. Intra-cerebral radiological response according to RECIST
criteria on the first scan to assess response to the novel agents was
recorded. For patients receiving ipilimumab, later scans were
checked for a possible delayed response. Finally, date of death or
last clinical review was recorded.
The msGPA was calculated as described previously (Box 1) for
all patients at the time of diagnosis of brain metastases. Patients
without imaging reports including number of brain metastases (15
patients) or for whom it was not possible to identify KPS at the
time of diagnosis of brain metastases (17 patients) were excluded.
Patients without a date of death were censored at their last date of
clinical follow-up for the survival analysis.
The Sperduto study does not report details of model coefficients,
hazard ratios, indices of discrimination or a baseline survival
function for the derivation cohort (Sperduto et al, 2012). This means
that direct statistical comparison was limited to use of KM methods
(Royston and Altman, 2013). KM survival curves were constructed
for Cohort I and Cohort II and these were compared with the
survival curves published for the derivation data set for the msGPA.
Despite the lack of statistical parameters available for comparison in
the derivation data set, the Cox proportional hazards model was
used to assess differences in survival between different prognostic
groups in the validation cohorts. In addition, Harrell’s c-index of
concordance was calculated for both cohorts. This is recommended
as a measure of discrimination (Royston and Altman, 2013) in
preference to testing for statistical significance between prognostic
groups in validation studies. Harrell’s c-index is defined as the
proportion of all usable (non-censored) patient pairs in which the
predictions and outcomes are concordant (Harrell et al, 1996). A
value of 0.5 indicates no predictive discrimination and a value of 1.0
indicates perfect separation of patients with different outcomes. The
c-index does not assess calibration.
To assess the impact of BRAF status and treatment with BRAF
inhibitors on survival in Cohort II, KM survival curves were
constructed for patients with BRAF wild-type vs BRAF mutant
tumours. Patients with BRAF mutant tumours were split into those
treated or not treated with a BRAF inhibitor after diagnosis of
brain metastases. The log-rank test was used to formally compare
survival between patients with BRAF wild-type tumours and
patients with BRAF mutant tumours irrespective of subsequent
treatment. The log-rank test was also used to compare survival of
patients with BRAF mutant tumours who did or did not receive a
BRAF inhibitor after diagnosis of brain metastases. Univariate and
multivariate Cox regression analysis was used to assess the impact
of novel targeted agents on survival, alongside previously identified
prognostic factors (Broadbent et al, 2004; Morris et al, 2004;
Hofmann et al, 2007). The proportional hazards assumption of the
Cox model was tested using Schoenfeld residuals. Any factor that
had a P-valueo0.1 on univariate analysis was entered into the
multivariate analysis. All statistical analysis was conducted using
STATA v13.1 (StataCorp LP, College Station, TX, USA).
Box 1. Scoring the melanoma-specific graded prognostic
assessment (msGPA)
msGPA score
Karnofsky performance status
90–100 2
70–80 1
o70 0
Number of brain metastases
1 2
2–3 1
43 0
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RESULTS
Overall 231 patients in Cohort I and 162 patients in Cohort II were
eligible for this analysis following exclusion of 21 patients due
to missing KPS (17 patients) or number of brain metastases
(15 patients). Baseline characteristics of the two cohorts are shown
in Table 1. Median survival in Cohort I was 3.6 months (95% CI
2.8–4.5 months) and in Cohort II was 4.4 months (95% CI 3.5–4.8
months). Patients in each of the different prognostic groups were
well-represented in both cohorts.
The KM curves shown in Figure 1 demonstrate that the msGPA
enabled good discrimination between all four prognostic groups in
Cohort I. However, in Cohort II, discrimination between groups
was less good, particularly between patients with msGPA scores of
2 and 3. KM curves for msGPA scores 1 and 4 separate clearly
from the rest of Cohort II, but the KM curves for msGPA scores 2
and 3 overlap for the first 6 months of follow-up and lie in close
proximity for the remainder of the study period.
Harrell’s c-index of concordance was 0.65 (95% CI 0.61–0.69) in
Cohort I and 0.67 (95% CI 0.63–0.72) in Cohort II. A probability of
concordance between observed and predicted outcomes of o0.7
indicates modest discrimination at best (Royston and Altman,
2013). Sperduto et al did not provide a c-index for their derivation
cohort for comparison (Sperduto et al, 2012).
Median survival times for Cohorts 1 and 2 are shown in Table 2,
together with median survival times from the Sperduto study
(Sperduto et al, 2012). Median survival times for the Sperduto
cohort differed considerably and were higher than both Cohorts I
and II in all four msGPA groups, indicating poor calibration of the
prognostic model. In GPA groups 3 and 4, median survivals were
more than 3 months higher in the Sperduto cohort than in Cohorts
I and II. For Cohorts I and II, the median survival times for the
four different groups are ranked in the order predicted by the
msGPA suggesting that, for this time point, discrimination of the
model is reasonable. However, as discussed earlier, discrimination
is less good in Cohort II at other time points. Hazard ratios for
death for patients in the different msGPA groups for Cohorts I and
II are also shown in Table 2. No data from Sperduto’s derivation
cohort are available for comparison, but, once again, the four
different groups are ranked in the order predicted by the msGPA
in both cohorts.
BRAF mutation status was available for 71 patients in Cohort
II—42 patients had a BRAF mutation, whereas tumours of
29 patients were BRAF wild-type. BRAF status was untested in
90 patients and unknown in 1 patient. The majority of untested
patients were diagnosed with brain metastases between 2008 and
2010, when routine BRAF testing was not available at our
institution. Survival of patients with BRAF wild-type tumours vs
those with a BRAF mutation, divided into those who did or did not
receive a BRAF inhibitor after diagnosis of brain metastases, is
shown in Figure 2. There was no difference in survival between
patients with BRAF mutation vs BRAF wild-type (log-rank test
P¼ 0.79). The KM curves, which are unadjusted for other
prognostic factors, suggest that patients receiving a BRAF inhibitor
after diagnosis of brain metastases had better survival outcomes
than patients with BRAF mutant tumours who did not receive this
treatment (log-rank test P¼ 0.029).
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Figure 1. Survival outcomes for patients with brain metastases from
melanoma. (A and B) Kaplan–Meier curves to show msGPA
for Cohort I (1997–2008) and Cohort II (2008–2013). Abbreviation:
msGPA¼melanoma-specific graded prognostic assessment.
Table 1. Basic demographics
Cohort I Cohort II
Total number of patients 231 162
Age, median (range) 55 (17–92) 58 (22–89)
Sex, n (%)
Male 153 (66) 70 (43)
Female 78 (34) 92 (57)
Number of brain metastases, n (%)
1 69 (30) 52 (32)
2–3 66 (29) 45(28)
43 96 (41) 65 (40)
KPS, n (%)
90–100 82 (36) 60 (37)
70–80 97 (42) 63 (39)
o70 52 (22) 39 (24)
Extra-cerebral disease, n (%)
Yes 186 (81) 149 (92)
No 44 (19) 13 (8)
Not available 1 0
Leptomeningeal disease, n (%)
Yes 7 (3) 8 (5)
No 223 (97) 150 (93)
Not available 1 4 (2)
Treatment for brain metastases, n (%)
WBRT 226 (98) 104 (65)
SRS 24 (10) 27 (17)
Neurosurgery 39 (17) 26 (16)
Chemotherapy 67 (29) 31 (19)
Novel targeted agenta 0 41 (25)
Best supportive care 0 20 (12)
Abbreviation: KPS¼Karnofsky performance status.
aIndividual novel agents are outlined in Table 3.
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Treatment with novel agents following diagnosis of brain metastases
included vemurafenib (21 patients), ipilimumab (23 patients) or
trametinib (1 patient). No patients received PD-1 antibodies. Intra-
cerebral responses to the novel agents on the first radiological
assessment of response are shown in Table 3. Overall 5 out of 45
patients experienced an intra-cerebral partial response to treatment,
whereas 13 out of 45 patients experienced stable disease in the brain.
No patients experienced a delayed response to ipilimumab in the brain.
Factors shown to predict survival on univariate analysis of
patients in Cohort II included KPS, number of brain metastases,
number of sites of extra-cerebral metastases, age and treatment
with novel agents. Presence of leptomeningeal disease was of
borderline significance (P¼ 0.07). On multivariate analysis all five
factors remained statistically significant predictors of survival
(Table 4); once again leptomeningeal disease was of borderline
significance (P¼ 0.06).
DISCUSSION
To our knowledge, this study is the largest to date that seeks to
validate the msGPA in a modern population. In the only other
study in a cohort of 51 patients (Nieder et al, 2011), poor
discrimination was reported between msGPA categories 0–1 and 2
using KM methods, and the authors concluded that the msGPA
does not facilitate appropriate selection of patients for best
supportive care. KPS and plasma lactate dehydrogenase levels
(LDH) were identified as the only significant prognostic factors. In
a slightly larger cohort of patients, the same authors found that
only KPS and number of brain metastases significantly predicted
prognosis (Nieder et al, 2012). A larger study of 251 patients
treated with SRS concluded that the diagnosis-specific GPA splits
patients into prognostically significant groups, but only 74 patients
had melanoma and no melanoma-specific KM curves were
reported. Therefore, the study is not informative about the
performance of the msGPA (Likhacheva et al, 2012).
The population in this external validation study is representative
of current UK practice. No baseline characteristics are available to
describe the North American derivation cohort (Sperduto et al,
2012); however, the treatments given suggest that it differs
considerably from the UK cohorts. For example, 16.7% of patients
in Cohort II of this study received SRS, while 12.3% received best
supportive care as compared with 76% and 0%, in Sperduto’s
derivation cohort (Sperduto et al, 2012). This is likely to be a
significant factor explaining why the calibration between median
survival outcomes in the derivation and validation data sets was
poor. The difference in calibration is most marked in msGPA
groups 3 and 4 and it is also possible that inferior therapies (e.g.,
less frequent use of SRS) in the UK resulted in inferior survival
outcomes. As the number of systemic therapies that demonstrate
intra-cerebral activity against metastatic melanoma increases (Long
et al, 2012; Margolin et al, 2012; Dummer et al, 2014), the use of
local treatments, such as SRS, for brain metastases is likely to
expand, even in the UK.
Table 2. Hazard ratios of death for Cohorts I and II and median survival for Cohort I and II, and the derivation data set by
Sperduto et al
Hazard ratio (95% CI)a Median survival, months (95% CI)
msGPA score Cohort I Cohort II Cohort I Cohort II Sperduto et al.
0–1.0 1 1 2.1 (1.8–2.4) 1.9 (1.3–2.2) 3.38 (2.5–4.3)
2 0.5 (0.36–0.70) 0.45 (0.30–0.66) 4 (3.0–4.5) 4.4 (3.8–6.0) 4.7 (4.1–5.4)
3 0.34 (0.24–0.49) 0.31 (0.20–0.51) 5.5 (4.9–6.7) 5.8 (3.3–7.9) 8.8 (6.7–10.8)
4 0.25 (0.15–0.41) 0.28 (0.17–0.47) 10.1 (5.4–12.2) 8.9 (5.1–12.1) 13.2 (9.1–15.6)
Abbreviations: CI¼ confidence interval; msGPA¼melanoma-specific graded prognostic assessment.
aHazard ratios not reported by Sperduto et al (2012).
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Figure 2. Kaplan–Meier curves to show survival according to BRAF
status and treatment with BRAF inhibitors (BRAFi) in Cohort II.
Table 3. BRAF status, novel agents and intra-cerebral
response to novel agents in Cohort II
BRAF status, n (%) n (%)
Mutant 42 (25.9)
Wild type 29 (17.9)
Untested 90 (55.6)
BRAF status unknown 1 (0.6)
Total 162
Novel agents used, n (%)
Vemurafenib 21 (46.7)
Ipilimumab 23 (51.1)
Trametinib 1 (2.2)
Total 45
Intra-cerebral radiological response to vemurafenib, n (%)
Partial response 4 (19)
Stable disease 10 (47.6)
Progressive disease 2 (9.5)
Clinical progression, no scan 3 (14.2)
Not available 2 (9.5)
Total 21
Intra-cerebral radiological response to ipilimumab, n (%)
Stable disease 3 (13.0)
Progressive disease 12 (52.2)
Clinical progression, no scan 5 (21.7)
Not available 3 (13.0)
Total 23
Intra-cerebral radiological response to trametinib, n (%)
Partial response 1 (100%)
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Differences in the routine surveillance of metastatic melanoma
between the UK and the US may be a further reason why
calibration of the msGPA was poor. In the UK, surveillance for
high risk stage III patients includes a brain scan, whereas for
patients with stage IV disease brain scans are usually only carried
out in response to neurological symptoms or prior to trial entry. In
contrast, in the US, routine surveillance for stage IV patients often
includes a brain scan. Brain metastases may, therefore, be detected
earlier in the natural course of the disease when the patient has no
or minimal symptoms and smaller metastases, meaning that
aggressive local treatment may be more feasible and more likely to
be effective.
While Cohort I and the original data set of Sperduto et al (2012)
had good discriminatory ability between groups, the msGPA
performed less well in Cohort II, particularly in patients with an
intermediate prognosis (msGPA groups 2 and 3). The time frame
and patients included in Cohort II are more relevant to current
practice. In addition, patients with an intermediate prognosis are
particularly in need of an efficient prognostic index to guide
selection for locally aggressive treatments such as SRS or
neurosurgery.
No significant differences in survival were seen between patients
with wild-type vs mutant BRAF. Twenty-one of 42 patients (50%)
with a BRAF mutation did not receive a BRAF inhibitor after
diagnosis of brain metastases, usually because it had been given
prior to development of radiologically visible brain metastases.
Patients with BRAF mutant tumours who did not receive a BRAF
inhibitor after the diagnosis of brain metastasis had a significantly
worse prognosis than those who did receive such treatment. This
finding is intriguing and certainly warrants further analysis in
prospective studies of BRAF inhibition in the context of intra-
cerebral disease.
Exposure to novel agents predicted for improved survival in
the multivariate analysis, which accounted for KPS, number of
brain metastases, leptomeningeal disease and extra-cerebral
metastases. The intra-cerebral radiological responses seen
suggest that such novel agents may exert their effects both inside
and outside of the brain. A possible interpretation of these data is
that patients with a future opportunity for targeted agents and
newly diagnosed brain metastases might be particularly appro-
priate for more aggressive treatment of intra-cerebral disease.
However, despite considerable progress in predicting which
patients will respond to novel agents (Snyder et al, 2014; Tumeh
et al, 2014), at present it remains difficult to reliably and
reproducibly predict outcomes and further biomarkers of response
are needed.
Other significant prognostic factors in the multivariate analysis
that are not represented in the msGPA include the number of sites
of extra-cerebral metastases and leptomeningeal disease. Both
factors have been identified in previous studies, including a
temporally distinct study at our institution (Morris et al, 2004).
Age was also a significant prognostic factor, this is represented in
the RPA classification of brain metastasis (Gaspar et al, 2000),
which has been validated in patients with melanoma (Morris et al,
2004). Despite previous work suggesting female patients had better
survival outcomes than male patients (Hofmann et al, 2007), our
study did not show significant survival differences between men
and women.
Table 4. Univariate and multivariate analysis of prognostic factors
Univariate analysis (n¼162) Multivariate analysis (n¼138)
Factor assessed No. Hazard ratio (95% CI) P-value No. Hazard ratio (95% CI) P-value
Karnofsky performance status
70 39 1 32 1
70–80 63 0.55 (0.36–0.83) 53 0.42 (0.26–0.69)
90–100 60 0.45 (0.30–0.69) o0.001 53 0.35 (0.21–0.57) o0.001
Number of brain metastases
43 65 1 51 1
2–3 45 0.83 (0.56–1.23) 41 0.88 (0.53–1.44)
1 52 0.41 (0.28–0.61) o0.001 46 0.43 (0.27–0.70) 0.001
Age (continuous) 162 1.02 (1.01–1.03) 0.001 138 1.01 (0.99–1.02) 0.05
Sex
Male 92 1
Female 70 0.88 (0.64–1.22) 0.44 NA NA NA
Sites of extra-cerebral metastases
Unknown 14 0
4þ 42 1 11 1
3 36 0.60 (0.38–0.95) 25 0.64 (0.39–1.06)
2 29 0.34 (0.20–0.56)) 27 0.34 (0.20–0.61)
1 30 0.31 (0.18–0.51) 34 0.29 (0.17–0.52)
0 11 0.26 (0.12–0.56) 0.001 41 0.22 (0.10–0.50) o0.001
Leptomeningeal disease
Unknown 4 0
No 150 1 132 1
Yes 8 2.05 (0.94–4.44) 0.07 6 2.45 (0.95–6.33) 0.06
Novel agents after diagnosis of BM
Unknown 11 0
No 111 1 99 1
Yes 40 0.42 (0.28–0.63) o0.001 39 0.43 (0.28–0.66) o0.001
BRAF status
Unknown 91
Wild type 29 1
Mutant 42 0.93 (0.56–1.55) 0.79 NA NA NA
Abbreviations: BM¼brain metastases; CI¼ confidence interval; NA¼not assessed.
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This study was a validation study that also explored new
predictive factors relevant to current melanoma treatment. It did
not aim to generate a new predictive model, which requires an
independent data set (Royston and Altman, 2013) and a greater
number of patients treated with a wider repertoire of novel targeted
agents. The data presented in this study suggest that development
of a new model incorporating factors unaccounted for in the
msGPA would improve individualised treatment.
Two other recently proposed prognostic indices for patients
with brain metastases treated with radiosurgery include the score
index for radiosurgery (SIR) and the basic score for brain
metastases (BSBM). The SIR includes age, KPS, systemic
metastases, number of brain lesions and volume of lesions treated
(Weltman et al, 2000). The BSBM is derived from KPS, control of
treated brain lesions and presence or absence of extra-cranial
disease (Lorenzoni et al, 2004). Of these, the BSBM has shown
better survival prediction than the SIR and RPA (Lorenzoni et al,
2009), and has recently been updated to also predict neurological
outcomes based on the addition of four brain factors (Serizawa
et al, 2014). Neither index has been evaluated in a contemporary
cohort of melanoma patients with brain metastases receiving novel
targeted agents, but they do contain parameters that may prove
important in risk stratification.
The retrospective nature of this analysis imposes some
limitations on its interpretation. Cohort I included no patient
receiving supportive measures alone and, thus, is unrepresentative
of routine UK practice at that time. Meanwhile, Cohort II may
have unintentionally excluded those patients with an accelerated
clinical deterioration who were unable to attend outpatients for
assessment or therapy. Despite recent data supporting LDH as an
important prognostic factor in metastatic melanoma (Long et al,
2012; Larkin et al, 2014), it was not included as a prognostic factor
because LDH was not measured routinely at our institution during
the study period. Finally, the study included a simple validation
method without detailed quantitative statistical parameters; how-
ever, these parameters were not published in the original study,
precluding direct comparison.
In conclusion, this study externally validating the msGPA shows
that this prognostic model has limited use in a modern population.
In particular, it performs poorly for patients with an intermediate
prognosis. Further work is needed to refine this model including
incorporation of biomarkers (BRAF, RAS, CTLA4 and PD-L1/
PD-1) and the effect of treatment options based on their presence
or absence. Other prognostic factors previously shown to be
important in this disease and excluded from the msGPA, including
LDH (Staudt et al, 2010; Eigentler et al, 2011; Nieder et al, 2011;
Partl et al, 2013), leptomeningeal disease (Morris et al, 2004),
extra-cerebral metastases (Broadbent et al, 2004; Raizer, 2006;
Rades et al, 2010) and size of intra-cranial metastases (Mathieu
et al, 2007; Likhacheva et al, 2012), may also be relevant to future
prognostic indices. Such indices are certainly needed to underpin
high-quality randomised controlled trials in an area with a wide
disparity in clinical care.
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